• Dicot Pharma has been granted a patent in 25 European countries covering the manufacturing process for its drug candidate LIB-01.
• The patent provides protection until 2043, complementing existing patents for the erectile dysfunction and premature ejaculation treatment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dicot Pharma AB published the original content used to generate this news brief on October 26, 2026, and is solely responsible for the information contained therein.